Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

Plants produce a wide diversity of compounds. Broadly, these are separated into primary metabolites, which are necessary for ...

From the time we are conceived and through old age, genetic mutations accumulate in all our tissues, eluding the body's ...

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

The Global Bioinformatics Market is expected to grow at a rate of 13-14% by 2029. The rising government initiatives and ...

Market Growth Driven by Declining Sequencing Costs, Rising Prevalence of Genetic Disorders, Expanding Clinical Applications, and Technologica ...

The Rise of a Frenzied Trading Style Cathie Wood, founder of ARK Invest, burst into investor consciousness in 2020 when her ...

Illumina, Inc. will acquire SomaLogic for $350 million plus performance-based milestones. The acquisition advances Illumina's multiomics strategy, combining SomaLogic's proteomics technology with ...

The NovaSeq X system, featuring Illumina’s XLEAP-SBS chemistry, can generate more than 20,000 whole genomes per year, more ...

Dr. Lal PathLabs Limited announces the addition of Illumina’s NovaSeq X Series to enhance genomic testing capabilities, ...

Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, ...